Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2022-08-29 Proxy Solicitation & In…
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
益丰药房关于召开2022年第四次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice for convening the 2022 fourth extraordinary general meeting of shareholders of Yifeng Pharmacy Chain Co., Ltd. It includes the meeting date, voting methods, agenda items for shareholder approval, and instructions for proxy voting. The content focuses on the announcement and procedural details of the shareholder meeting rather than the meeting materials or results themselves. There is no financial report or earnings data presented, nor is it a transcript or management discussion. The document is a formal announcement of the meeting and its agenda, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting and agenda rather than solicitation materials or voting results, it aligns best with Proxy Solicitation & Information Statement (PSI). The document length is about 4720 characters, which is consistent with a detailed meeting notice and proxy statement. Therefore, the classification is PSI with high confidence.
2022-08-29 Chinese
益丰药房2022年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2022 年半年度报告摘要" which translates to "2022 Half-Year Report Summary". It contains detailed financial data for the half-year period, including total assets, net profit, revenue, shareholder information, and operational highlights. The document explicitly states it is a half-year report summary and includes substantive financial data and analysis for the period ending June 30, 2022. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data. The document is over 6,000 characters, so it is not a mere announcement or publication notice. Therefore, the correct classification is IR with high confidence. H1 2022
2022-08-29 Chinese
益丰药房公开发行可转换公司债券的可行性报告（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "Feasibility Analysis Report (Revised)" for the use of funds raised from a public issuance of convertible corporate bonds by 益丰大药房连锁股份有限公司. It details the investment plans for the raised funds, including specific projects, investment amounts, implementation necessity, feasibility, and expected impacts on the company's operations and financial status. The content focuses on capital raising and the intended use of proceeds from the convertible bonds issuance, including infrastructure projects, digital platform upgrades, new store openings, and working capital supplementation. There is no indication that this is a full annual or interim financial report, audit report, earnings release, or other types of filings. Instead, it is a detailed capital/financing update related to the use of proceeds from a financing activity. Therefore, the document best fits the category of Capital/Financing Update (CAP). The document length (over 13,000 characters) and detailed content support this classification with high confidence.
2022-08-29 Chinese
益丰药房公开发行可转换公司债券预案（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled "公开发行可转换公司债券预案（修订稿）" which translates to "Public Offering Convertible Corporate Bonds Proposal (Revised Draft)". It contains detailed information about the issuance of convertible bonds, including issuance scale, terms, interest rates, conversion price adjustments, redemption and repurchase clauses, use of proceeds, and financial statements for multiple years. The document is a comprehensive proposal related to capital raising through convertible bonds, including financial data and management discussion relevant to the issuance. This fits the definition of a Capital/Financing Update (CAP), as it provides detailed updates on the company's fundraising and capital structure changes. It is not an announcement of a report, nor a full annual or interim report, but a detailed financing plan and proposal. The document length is substantial (15,000 characters), and it contains substantive financial data and discussion related to the financing activity. Therefore, the appropriate classification is CAP with high confidence.
2022-08-29 Chinese
益丰药房关于增加银行综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from the company about increasing its comprehensive bank credit limits. It details the amounts of credit increase from various banks and the total new credit limit. There is no financial statement, earnings data, or detailed financial analysis. The document is focused on financing activities, specifically credit facilities and bank loans. It is not a full financial report, audit, or earnings release. Therefore, it fits best under Capital/Financing Update (CAP). The document length is short and it is not merely announcing a report publication, so it is not RPA. Hence, the classification is CAP with high confidence.
2022-08-29 Chinese
益丰药房2022年限制性股票激励计划激励对象名单
Remuneration Information Classification · 95% confidence The document is a list of incentive plan participants for a 2022 restricted stock incentive plan of a company. It contains names and positions of senior management and core personnel. There is no financial data, no discussion of financial results, no regulatory body references, no voting results, no legal proceedings, no capital changes, and no meeting materials. The document is essentially an announcement or disclosure of the incentive plan participants, which relates to management and executive compensation information. This fits best under the category of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors. The document length is about 4932 characters, which is not very long but contains detailed lists of personnel involved in the incentive plan, consistent with remuneration disclosures.
2022-08-29 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.